Case Western Reserve University
School of Law Scholarly Commons
Faculty Publications
2009

Making All the Children Above Average: Ethical and Regulatory
Concerns for Pediatricians in Pediatric Enhancement Research
Jessica W. Berg
Case Western University School of Law, jessica.berg@case.edu

Maxwell J. Mehlman
Case Western University School of Law, maxwell.mehlman@case.edu

Daniel B. Rubin
Eric Kodish

Follow this and additional works at: https://scholarlycommons.law.case.edu/faculty_publications
Part of the Health Law and Policy Commons

Repository Citation
Berg, Jessica W.; Mehlman, Maxwell J.; Rubin, Daniel B.; and Kodish, Eric, "Making All the Children Above
Average: Ethical and Regulatory Concerns for Pediatricians in Pediatric Enhancement Research" (2009).
Faculty Publications. 844.
https://scholarlycommons.law.case.edu/faculty_publications/844

This Article is brought to you for free and open access by Case Western Reserve University School of Law Scholarly
Commons. It has been accepted for inclusion in Faculty Publications by an authorized administrator of Case
Western Reserve University School of Law Scholarly Commons.

Clinical Pediatrics
http://cpj.sagepub.com/

Making All the Children Above Average: Ethical and Regulatory Concerns for Pediatricians in
Pediatric Enhancement Research
Jessica W. Berg, Maxwell J. Mehlman, Daniel B. Rubin and Eric Kodish
CLIN PEDIATR 2009 48: 472 originally published online 21 January 2009
DOI: 10.1177/0009922808330457
The online version of this article can be found at:
http://cpj.sagepub.com/content/48/5/472

Published by:
http://www.sagepublications.com

Additional services and information for Clinical Pediatrics can be found at:
Email Alerts: http://cpj.sagepub.com/cgi/alerts
Subscriptions: http://cpj.sagepub.com/subscriptions
Reprints: http://www.sagepub.com/journalsReprints.nav
Permissions: http://www.sagepub.com/journalsPermissions.nav
Citations: http://cpj.sagepub.com/content/48/5/472.refs.html

Making All the Children Above Average:
Ethical and Regulatory Concerns for
Pediatricians in Pediatric Enhancement
Research

Clinical Pediatrics
Volume 48 Number 5
June 2009 472-480
© 2009 Sage Publications
10.1177/0009922808330457
http://clp.sagepub.com
hosted at
http://online.sagepub.com

Jessica W. Berg, JD, Maxwell J. Mehlman, JD, Daniel B. Rubin, MA,
and Eric Kodish, MD
Building on the knowledge generated by the long history
of disease-oriented research, the next few decades will
witness an explosion of biomedical enhancements to
make people faster, stronger, smarter, less forgetful, happier, prettier, and live longer. Growing interest in pediatric
enhancements is likely to stimulate the conduct of
enhancement research involving children. However,
guidelines for the protection of human subjects were
developed for investigations of therapeutic modalities. To
date, virtually no attention has been paid to whether

I

n spite of ethical objections, biomedical enhancements for pediatric populations are substantially
available and in serious demand. Parents have
reportedly sought human growth hormone injections for children of normal height to make them
better basketball players.1 In 2006, 1.4% of cosmetic
procedures were performed in persons below 18
years of age, including more than 16 000 rhinoplasties, almost 8000 Botox injections, and more
than 3000 breast augmentations.2 Prescribing patterns for Ritalin (methylphenidate) suggest that the
drug is being used in an effort to improve focus and
cognitive skills in normal as well as in attention-deficit children.3-5 Given the fierce competition for
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these rules would be appropriate for investigations to
establish the safety and efficacy of technologies intended
for enhancement rather than therapeutic uses and, if not,
whether ethically acceptable rules could be designed.
This article discusses whether the current guidelines for
pediatric research provide appropriate protections for
pediatric subjects in enhancement research and considers what additional protections might be necessary.
Keywords:   enhancement; research; genetics; ethics

scarce societal resources, such as access to elite educational institutions, pediatric demand for safe and
effective biomedical enhancements is likely to grow.
Moreover, because enhancements are not covered by
health insurance, they can be provided free of price
and utilization controls, making them a potentially
financially attractive addition to a medical practice.
To date, no intervention has been approved by the
Food and Drug Administration (FDA) specifically for
enhancement use in the pediatric population, and
there have been few reported clinical trials of enhancement interventions in this population. By and large,
pediatricians who wish to prescribe drugs for enhancement purposes, therefore, must do so on an off-label
basis, and surgeons who perform pediatric cosmetic
surgery must rely on anecdotal evidence of safety and
effectiveness. Growing interest in pediatric enhancements, however, is likely to stimulate the conduct of
enhancement investigations in children. Formal trials
may be needed to assess the safety of off-label
enhancement use of approved products. In addition,
manufacturers may sponsor studies to obtain FDA
approval for enhancement indications to avoid FDA
restrictions on marketing products for off-label uses
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and to meet agency requirements that product approvals be based on clinical investigations in pediatric as
well as in adult populations. Pediatricians may, therefore, find themselves being asked to serve as investigators and as members of institutional review boards
(IRBs) evaluating proposed pediatric enhancement
studies, they may be consulted by families about
enrolling their children as subjects, and they may participate in professional and public debate about the
wisdom of conducting this type of research. It is
therefore important to consider whether this type of
research would ever be ethical and, if so, under what
conditions.

Distinguishing Between
Enhancement and Treatment
Before considering how enhancement technologies
should be tested in children and whether the current guidelines for pediatric research provide an
appropriate framework, some definitional issues
must be addressed. We focus on biomedical interventions both because those are likely to involve a
greater degree of risk (and thus be of more concern
from a pediatric research standpoint) and because
we wanted to be able to distinguish these issues
from the multitude of common parental choices
regarding their children’s activities, such as tutoring,
music lessons, and the like, designed to create
smarter and more talented youth. We adopt the following working definition of a biomedical enhancement: It is an intervention that uses medical and
biological technology to improve performance,
appearance, or capability and does not aim to prevent, treat, or mitigate the effects of a disease or
disorder. Thus, according to Julian Savulescu, it
increases the chances of leading a good life.6
The distinction between enhancement and healthoriented research, however, is not a bright line.
Immunization, which makes children’s immune systems better than normal, would not qualify as an
enhancement because its aim is to prevent disease.
Similarly, a drug to improve cognitive function in children with below-normal cognitive ability ordinarily
would not be considered an enhancement. But consider a proposed trial of a hypothetical pharmacological
agent intended to improve pediatric cognitive functioning, which acts by increasing short-term memory, consolidating long-term memory, increasing the speed and

accuracy of mental calculation, increasing attention
span, facilitating abstract integrative thinking, and/or
improving inventiveness and creativity. If the drug were
found to be so effective that some subjects exceeded
population norms for cognitive functioning, the drug
clearly would qualify as an enhancement. But many
also would regard the experimental intervention as an
enhancement if it improved cognition in normal children, even if their performance remained within population norms. Similar concerns have been raised by the
use of growth hormone for children who are within the
normal height range for the population.7
The concept of normality, of course, is itself elusive. In some cases, it refers to the frequency with
which a trait or capability occurs within a population. In other circumstances, it may have no relationship to the distribution of a trait. Normal eyesight is
deemed to be 20/20, for example, but only about 35%
of adults have 20/20 vision without some form of
correction.8 Standards of normality may also vary
from place to place and time to time, and can be
expected to change as the use of enhancements
increases. For example, body shapes that were associated with health a hundred years ago are now considered obese. Furthermore, the concepts of disease
and disorder themselves may be hard to pin down.
Homosexuality is regarded by some as a disorder
rather than a lifestyle. Moreover, there is a tendency
to regard more and more health states as diseases
and more and more interventions as treatments.
In short, the distinction between health-oriented
and enhancement research will not always be clear,
and invariably, there will be borderline cases. Moreover,
studies designed initially as health-oriented clinical
studies but that use normal subjects as controls might
detect enhancement as well as health-oriented benefits. For example, in the process of studying the drug
Tolcapone, an inhibitor of catecholamine-O-methyltransferase, to ascertain if it improved cognitive function in schizophrenics, Apud et al9 detected a
cognition-enhancing effect in their normal controls.
This raises the possibility that investigators who are
concerned that they might not be allowed to conduct enhancement studies in children might seek
to hide enhancement research within health-
oriented investigations. Insofar as enhancement
research raises special ethical concerns, pediatricians who serve on IRBs must be aware of the
possible admixture of medical research and
enhancement objectives.
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The difficulty of clearly identifying enhancement
research complicates the task of determining the
conditions, if any, under which it would be ethical to
perform such research with children as subjects.
Nonetheless, we believe that our working definition
will be sufficient to allow us to draw some initial
conclusions about the ethical propriety of conducting
pediatric enhancement trials under the current regulatory framework and the sufficiency of the protections afforded under that framework. The extent to
which one remains troubled by the borderline cases
may depend on how well the existing safeguards for
pediatric research are viewed as sufficient.

The Current Regulatory Framework
Although research ethics is not limited to the federal
regulations governing human subjects, the regulations provide a useful starting point for analysis. For
example, how should a pediatrician serving on an
IRB evaluate the hypothetical study of the cognitive
enhancement described previously under the federal
regulations governing research with human subjects? Research with children is subject to the standard requirements in the regulations of the
Department of Health and Human Services (HHS)
and the FDA governing research with competent
adults,10-12 which mandate that properly constituted
IRBs assure themselves that the investigators have
maximized the benefits and minimized the risks;
that the risks are reasonable in relation to the anticipated benefits, including benefits to subjects and
the importance of the knowledge to be gained; that
subject selection is equitable; and that appropriate
informed consent will be obtained from the subjects.
Mehlman and Berg13 discuss the ethical issues
raised by enhancement research under the general
research requirements elsewhere, and we address
these only to the extent that there are specific issues
raised by the inclusion of children. This article
focuses primarily on the additional protections that
apply to research involving children, under Subpart D
of the HHS regulations (corresponding in most details
to Subpart D of the FDA regulations).

General Protections: Risk–Benefit
and Equitable Subject Selection
For pediatricians serving as IRB members or clinical
investigators, it is important to consider whether the

potential benefits outweigh the risks. Many bioethicists and health care professionals object to giving
biomedical enhancements to children on a wide
variety of grounds, including that it would deprive
them of an “open future”14,15 and that by turning
childhood into a proving ground for traits that serve
parental or socially reinforced ambitions, enhancements may eclipse the intrinsic value of childhood
as a time for exploration and self-cultivation. The
American Society of Plastic Surgeons disapproves of
breast augmentation in teenagers below 18 because
they may not have reached full physical development and because they may lack the maturity to
make informed decisions.16 In connection with
sports, the American Academy of Pediatrics has
declared that “the intentional use of performance
enhancement is unfair, and therefore morally and
ethically indefensible.”17 Moreover, enhancements
may produce particularly serious side effects in children, as is the case with anabolic steroids and other
ergogenic drugs.18,19 According to these views, there
would never be any net benefit to society in giving
enhancements to children, and therefore, it would
never be ethical to enroll children in clinical trials of
biomedical enhancements.
On the other hand, the potential benefits of an
experimental enhancement intervention could outweigh the risks, such that it might be ethical
to conduct a study in an appropriate pediatric
population under certain carefully controlled conditions. The experimental cognition-enhancing drug
described in the previous section might be one such
candidate, especially if it had been studied extensively in adults and found to be extremely effective
while producing at most only minor side effects in a
very small number of subjects and if there were no
physiological or pharmacological reasons to suspect
that the drug would perform significantly less effectively or be substantially less safe in pediatric subjects. In fact, there have been at least 7 studies on
the effects of caffeine in normal children.20 The
potential benefits of an experimental drug that produced cognition-enhancing effects in adults superior to caffeine, especially by enhancing higher order
types of cognitive ability and with fewer side effects,
might be considered to outweigh the risks sufficiently to permit at least limited study in certain
pediatric subjects. Pediatricians who believe that the
goals of enhancement are inconsistent with the best
interests of children and the ethical dimensions of
medicine have the right to desist from engaging in
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enhancement research and to discuss their ethical
reservations with patients and their families. At the
same time, however, they have a responsibility to
provide information about the risks and potential
benefits of participating in enhancement research in
an accurate and unbiased manner.
Even if risks and benefits balance out in the
context of the specific trial, there are broader issues.
It is unclear to what extent IRBs are authorized to
consider the ethical and social implications of this
type of research. On one hand, IRBs may approve a
proposed study only if they conclude that the risks
are reasonable in relation to the anticipated benefits,
including benefits to subjects and the importance of
the knowledge to be gained. On the other hand, the
regulations specifically prohibit IRBs from considering “possible long-range effects of applying knowledge gained in the research (for example, the possible
effects of the research on public policy).”21(§46.111(a)(2))
Thus it appears that IRBs are allowed to consider
long-term benefits to society as a whole but not
potential long-term societal risks. This might be
interpreted as preventing IRBs from rejecting a protocol for a biomedical enhancement study in children on the basis that providing enhancements to
children would be bad public policy, for example,
because it might limit future children’s right to an
open future. This limitation is not unique to research
involving children nor to enhancement research,
and thus we simply note it here and consider it in
greater detail elsewhere (Juengst & Rubin, “LongTerm Benefits,” unpublished draft manuscript).
Another general regulatory requirement is that
subject selection be equitable and that the burdens
and benefit of research be fairly distributed. There
is some concern that enhancement benefits in
research would be especially attractive to less affluent families but that because enhancements would
not be covered by third-party health insurance,
they would be available outside of the experiment
only to families with sufficient resources to pay for
them out-of-pocket. For example, the use of prescription psychostimulants, including presumably
their use to enhance cognition, is positively correlated with higher economic status and greater
access to health care resources.22 Consequently,
risks inherent in the experimentation might be
borne by persons least likely to obtain the benefits
from the experimental intervention outside of the
experiment. This potential inequity will exist for
both pediatric and adult subject populations but

may be exacerbated in pediatric populations. There
is some evidence that poor and minority children
are more likely to be enrolled in health-oriented
pediatric trials requiring healthy subjects.11(p44) This
same problem may occur for trials of enhancement
interventions, which also require healthy volunteers. Justice concerns may dissuade pediatricians
from pursuing enhancement research.

Specific Protections: Assent and Parental
Permission
Risk–benefit evaluation and subject selection analysis are only part of the regulatory protections. In
addition, subjects must give their informed consent
to be enrolled in a clinical trial. In the case of children, their parents or legal guardian must give permission, and the children themselves must give their
“assent.” Enhancement research raises concerns
regarding both the role of the parents and the role of
the children.
Some ethicists believe that parents who
enhanced their children would be jeopardizing their
children’s health to further their own ambitions or
social status, or that they would be valuing the children too much in terms of their capabilities, that is,
“commodifying” them.23 On the other hand, parents
clearly have broad latitude in determining how to
bring up their children, including what risks to
expose them to and how to shape and maximize
their talents. It is unclear why parents who can
enroll their children in experimental educational
settings, for example, should be discouraged from
enrolling their children in a study simply because it
involves a biomedical enhancement, assuming risks
were acceptable. Moreover, the concerns raised by
the involvement of children in enhancement
research wane as the age of the subjects increases,
and they near the decisional capacity of adults. The
question ought to be whether reasonable parents,
being adequately informed about the risks and
potential benefits, and having paramount regard for
their children’s welfare could give permission for
their children to participate in a particular experiment. The debate about parental permission for
enhancement research is at base a debate about
whether parents have the ability to assent to their
children’s participation in any research not designed
to provide a direct, health-oriented benefit.
Assuming, without argument, that parents do
retain this authority,24 enhancement research raises
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some novel concerns. First, as with any clinical trial,
it is important that parents avoid a type of “therapeutic misconception” that subjects invariably will
receive whatever enhancement benefit the experimental intervention is assessing.25 This may be made
more complicated by the fact that although the benefit is not directed at health-oriented therapeutic
ends, the subjects, along with their parents, may be
expecting a direct “therapeutic” benefit. There is little
research on the implications of the therapeutic misconception for children’s assent and for parental
permission26(pp302-303) and no research addressing its
role in an enhancement context.13 Second, and perhaps more significantly, it is not clear how to categorize the benefits of enhancement research under a
regulatory structure that assumes that research studies can be divided clearly into either health-oriented
or non-health-oriented studies. Subpart D, described
in more detail below, depends on determinations of
benefit (and risk), and thus, the acceptability of an
enhancement study will depend on how enhancement benefits are classified. There are 4 categories of
research allowed with children, corresponding to
regulatory sections 404 through 407, and each is
discussed in detail below.
Subpart D specific protections. Section 404 allows
IRBs to approve research with children that entails
no greater than “minimal risk.” According to the
regulations, minimal risk means that “the probability and magnitude of harm or discomfort anticipated
in the research are no greater in and of themselves
than those ordinarily encountered in daily life or
during the performance of routine physical or psychological examinations or tests.”21(§46.102(i)) A 1977
report of the National Commission for the Protection
of Human Subjects of Biomedical and Behavioral
Research on research involving children recommended that the ages of potential subjects should
be taken into account in considering what risks are
ordinarily encountered in daily life. It also provided
a nonexclusive list of minimal-risk procedures: “routine immunization, modest changes in diet or schedule, physical examination, obtaining blood or urine
specimens, developmental assessments, . . . questionnaires, observational techniques, noninvasive
physiological monitoring, [and] psychological tests
and puzzles.”27(ppxx-xxi,23,25) The Institute of Medicine’s
Committee on Ethical Conduct of Clinical Research
Involving Children focuses on well-child visits as

the standard against which to judge minimal
risk.28,29(pp597-599) Others have argued that the minimal-risks standard is incoherent, and the survey by
Shah et al30 of IRB chairs reveals both wide variation in and illogical views about what constitutes
“minimal risk.” Although we agree that more work
must be done to clarify the concept of minimal risk,
it is very likely that experiments in which child subjects were given biomedical enhancements would
be deemed to present greater than minimal risk by
most IRBs, so section 404 would not apply.
Section 405 allows an IRB to approve research
with children that entails greater than minimal
risk as long as there is a prospect of direct benefit
to the individual subjects from the intervention in
question or the protocol entails “a monitoring
procedure that is likely to contribute to the subject’s well-being.”21(§46.405) The IRB must determine that the risks are justified by the anticipated
benefits to the subjects and that the benefit is at
least as favorable as that presented by available
alternative interventions. The regulations fail to
define “direct benefit” and thus provide no guidance on whether a direct enhancement benefit
would qualify as a benefit under section 405. The
survey by Shah et al30 demonstrated that IRB
chairs were unclear about what constituted a
direct benefit. The National Commission’s report
explaining the importance of research involving
children emphasized, on one hand, the need to
gain knowledge about innovative “treatments,”
but the Commission also acknowledged that
research will be important to evaluate nonmedical
practices.27(ppxx-xxi,23,25) Moreover, the regulation
speaks in terms of “direct benefit” rather than
direct medical benefit. Therefore, it might be possible to conduct enhancement research presenting
more than minimal risk on children under section
405, so long as the IRB determined that the morethan-minimal risks were balanced by the potential
benefits to the subjects.
Section 406 deals with research that presents a
“minor increase over minimal risk.” Like the concept
of “minimal risk” itself, this standard is not well
defined, and Shah’s survey showed that IRB chairs
were uncertain about how to apply it. In determining
whether a proposed study would represent a minor
increase over minimal risk, IRBs are told that the
interventions must be reasonably commensurate with
“actual or expected medical, dental, psychological,
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social or educational situations.”21(§46.406(b)) As the
National Commission explained, “the requirement of
commensurability of experience should assist children who can assent to make a knowledgeable decision about their participation in research, based on
some familiarity with the intervention or procedure
and its effects.”27(ppxx-xxi,23,25) Under section 406, the
experimental intervention must be “likely to yield
generalizable knowledge about the subjects’ disorder
or condition which is of vital importance for the
understanding or amelioration of the subjects’ disorder or condition.”21(§46.406(c)) On its face, this requirement seems to indicate that research under section
406 is appropriate only in subjects who have a “disorder or condition.” But the regulations do not
define “disorder or condition.” Therefore, it is conceivable that section 406 might permit enhancement studies to be conducted on subjects who fall
within the lower end of the normal range for the
target trait, such as height or cognitive ability. In
other words, “falling below the normal range” may
be considered a disorder or condition under the
regulations. The interpretation of “disorder or condition” is also important because of the tendency to
“medicalize” what were regarded previously as behavioral problems in children.31
The final section of the regulations pertaining to
research in pediatric subjects, section 407, allows
research “not otherwise approvable” if both the IRB
and the Secretary of HHS find that “the research
presents a reasonable opportunity to further the
understanding, prevention, or alleviation of a serious
problem affecting the health or welfare of
children.”21(§46.407) This might enable risky pediatric
enhancement research to proceed on the basis that
the risks to the subjects are outweighed by the
broader benefits that safe and effective enhancements might offer children as a group.
IRBs make the initial determination as to whether
a protocol should go through the 407 review process.
After referral by an IRB, the NIH Office for Human
Research Protections (OHRP), the oversight body
for the federal research regulations, convenes a panel
of experts in pertinent disciplines, referred to as a
407 Panel, to review the protocol and make recommendations to the secretary of HHS.32 The 407 process has been criticized on a number of grounds,
including that panels may lack both appropriately
broad expertise and public transparency.33

Some sense of how the 407 process might function in the case of an enhancement study can be
gleaned from a proposed experiment titled “Effects of
a Single Dose of Dextroamphetamine in Attention
Deficit Hyperactivity Disorder: A Functional Magnetic
Resonance Study.”34 The authors of this proposal
sought permission to conduct a double-blind placebocontrolled study of the effects of dextroamphetamine
on children with attention-deficit hyperactivity disorder (ADHD) as well on their non-ADHD peers. Under
this research plan, these non-ADHD children, who
exhibited no symptoms of this condition, would receive
dextroamphetamine, a potent psychostimulant, which
along with methylphenidate is reported to be the cognition-enhancing drug of choice among students in
higher education.35 The goal of the study was to determine whether stimulant medication caused different
patterns of neural activation, as measured by MRI, in
children with ADHD as compared with children who
did not have this condition. If so, then an MRI might
be a useful diagnostic tool for ADHD. The protocol
was submitted to the IRB at the National Institutes of
Mental Health on October 28, 2003. The IRB could
not agree on whether the study represented greater
than minimal risk, even though it would expose healthy
children to a controlled substance that has potential
for abuse/addiction.36 Therefore, the IRB voted to refer
the protocol to a 407 panel for further review. The
panel was charged with determining whether
risks to the subjects [are] reasonable in relation to
the anticipated benefits, and is the research likely
to result in generalizable knowledge about the subjects disorder or condition; and . . . [d]oes the
research present a reasonable opportunity to further the understanding, prevention, or alleviation
of a serious problem affecting the health or welfare
of children?36

The panel agreed that the study should be performed and recommended that it be approved by the
secretary of HHS. However, on March 7, 2005, the
investigators withdrew the protocol following a black
box warning regarding the risk of stroke for children,
which was issued for dextroamphetamine in the
Canadian market.36 This experience suggests that
there might be circumstances in which a 407 panel
would allow studies of biomedical enhancements in
pediatric subjects.
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Recommendations
From this effort to apply the current federal regulations to pediatric research specifically involving
biomedical enhancements, it becomes clear that
the regulations do not clearly prohibit the conduct
of enhancement experiments on children, and they
also do not provide clear guidance on the circumstances, if any, under which this research should
proceed. One way to address this problem is for
HHS and/or FDA to issue additional guidance for
IRBs regarding the way in which enhancement
research should be evaluated under existing guidelines and the role of the 407 process in this context. Perhaps HHS and FDA should consider
establishing specific regulations to govern the conduct of research on biomedical enhancements,
especially research involving children.
Given the wide variation in IRB review and concerns about the 407 process, it may be advisable to
establish a special federal body to review proposals
for pediatric enhancement research, similar to the
Recombinant DNA Advisory Committee, which was
established to address concerns about the risks
posed by recombinant DNA technology.37 IRBs confronted with protocols for pediatric enhancement
research would refer them to this body, which would
include ethicists and members of the public as well
as pediatricians, researchers, and experts in child
psychology and development, and which would be
charged with striking a proper balance between the
potential benefits of the research and the paramount need to protect the welfare of children as
subjects. A new process, however, may be extremely
expensive to implement. Moreover, because there is
clear overlap between health-oriented research and
enhancement research, it may be difficult for IRBs
to identify which protocols should go to the special
review body.
Even if specific guidelines, review processes, or
regulatory oversight for enhancement research are not
warranted, the application of the regulatory framework to pediatric enhancement research highlights a
number of problems in the existing regulations, which
should be addressed. Others have pointed out the
difficulty of interpreting the phrases “minimal risk”
and “minor increase over minimal risk,” but enhancement research also raises questions about how to
evaluate direct but non-health-oriented benefits.
There have already been discussions in the literature

about how to assess a range of nonhealth benefits
such as money and altruistic feelings, but enhancement benefits stretch the concept of direct benefit in
different ways. The pediatric regulations rely heavily
on the definitions of risk and benefit for determining
what categories of research are allowable. Likewise,
the scope of parental authority to grant permission
for children to participate rests on an understanding
of whether enhancement research involves acceptable benefits. Additionally, as pointed out above, we
must consider whether to remove the regulatory
limitation on IRBs’ consideration of long-range
effects of applying knowledge. This issue will have
broad implications for many types of research.
Besides concerns about the regulatory protections, there are other ethical questions that should
be addressed. Specifically, should we, as a society, be
funding either this type of research or these types of
interventions? From a policy standpoint, some pediatricians might object to publicly funded pediatric
enhancement research on the ground that research
funds should be allocated instead to health-oriented
investigations. Even privately funded research might
be objectionable if it improperly diverted scarce
resources, such as the limited number of pediatric
subjects and research institutions, from more socially
compelling projects. Although funding sources,
therefore, must consider carefully the value of the
research they support, it is not clear that enhancement research should always be considered less
socially valuable than health-oriented research. A
study of the hypothetical cognitive enhancement
drug described earlier, for example, may well deserve
priority over an experiment concerning a minor disease or condition.
Another concern is that enhancement research
could direct public resources toward providing access
to enhancements rather than toward more promising
options. A cognition-enhancing drug, for instance,
even one that was inexpensive and widely available,
might produce less total improvement in cognitive
ability than early education, lead abatement, or better
prenatal and early-childhood nutrition. This requires
careful evaluation of the cost-effectiveness of competing
alternatives for public investment.
Finally, if the burdens of enhancement research
fall unfairly on low-income populations, perhaps we
have a societal responsibility to ensure access to safe
and highly effective enhancements for low-income
families. In terms of enhancement trials themselves,
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one solution would be to offer subjects free or
affordable access in the future to any interventions
that emerged from the experiment.

Conclusion
Biomedical enhancement research raises complex
ethical issues. Some of the issues raised have broader
implications for a variety of pediatric research. Given
the growing demand for pediatric enhancements, we
must consider now the appropriate safeguards for trials of new interventions. Better guidance is needed
from HHS and FDA regarding some aspects of the
current regulations. Pediatricians must consider
whether or not this research should be conducted,
what information should be given to patients and
families interested in this research, and how public
policy should be shaped so that children who are
potential research subjects are adequately protected.
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